Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants

Vaccine

Volumn 26, Issue 18, 2008, Pages 2234-2241

  Gatchalian, Salvacion ^a   Yao, Yafu ^b   Zhou, Benli ^b   Zhang, Lei ^b   Yoksan, Sutee ^c   Kelly, Kim ^d   Neuzil, Kathleen M ^d   Yaïch, Mansour ^e   Jacobson, Julie ^d  

^a RESEARCH INSTITUTE FOR TROPICAL MEDICINE   (Philippines)

^b Chengdu Institute of Biological Products   (China)

^c MAHIDOL UNIVERSITY   (Thailand)

^d PATH   (United States)

^e NONE   (France)

Author keywords

Concomitant administration; Japanese encephalitis vaccine; Measles vaccine

Indexed keywords

ANTIBODY; DIPHTHERIA TETANUS VACCINE; JAPANESE ENCEPHALITIS VACCINE; LIVE ATTENUATED JAPANESE ENCEPHALITIS VACCINE; MEASLES VACCINE; POLIOMYELITIS VACCINE; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; EPIDEMIC ENCEPHALITIS; HUMAN; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INFANT; MEASLES; MONOTHERAPY; PEDIATRICS; PHILIPPINES; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTIBODIES, VIRAL; ENCEPHALITIS, JAPANESE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOGLOBULIN G; INFANT; JAPANESE ENCEPHALITIS VACCINES; MALE; MEASLES; MEASLES VACCINE; NEUTRALIZATION TESTS; PHILIPPINES; VACCINES, ATTENUATED;

EID: 42449133708     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.02.042     Document Type: Article

References (27)

1. Japanese encephalitis page. World Health Organization website. Available at: www.who.int/vaccine_research/diseases/vector/en/index1.html (accessed 31 May 2007).
2. Solomon T., Thao L.T., Dung N.M., Kneen R., Hung N.T., Nisalak A., et al. Rapid diagnosis of Japanese encephalitis by using an immunoglobulin M dot enzyme immunoassay. J Clin Microbiol 36 (1998) 2030-2034
3. Halstead S.B., and Tsai T.F. In: Plotkin S., and Orenstein W. (Eds). Japanese encephalitis (2004), WB Saunders, Vaccines. Philadelphia 919-958
4. Tsai TF. New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand, 13-15 October 1998. Vaccine 2000;18 (Suppl. 2):1-25.
5. Solomon T., Dung N.M., Kneen R., Gainsborough M., Vaughn D.W., and Khanh V.T. Japanese encephalitis. J Neurol Neurosurg Psychiatry 68 (2000) 405-415
6. Tandan J.B., Ohrr H., Sohn Y.M., Yoksan S., Ji M., Nam C.M., et al. Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: A case-control study in Nepalese children 5 years after immunization. Vaccine 25 (2007) 5041-5045
7. World Health Organization. Third Biregional Meeting on the Control of Japanese Encephalitis Meeting Report. Manila: WHO; 2007. Available at: http://www.wpro.who.int/NR/rdonlyres/50129D1D-E9B3-4707-A62E0A541DBC3032 /0/MTGRPT_JEBireg3.pdf.
8. World Health Organization. Safety of SA 14-14-2 Japanese encephalitis vaccine. Wkly Epidemiol Rec 28 (2005) 242-243
9. Rojanasuphot S., Nachiangmai P., Srijaggrawalong A., and Nimmanitya S. Implementation of simultaneous Japanese encephalitis vaccination in the expanded programme on immunization of infants. Mosquito-borne Dis Bull 9 (1992) 86-92
10. Fletcher M.A., Fabre P., Debois H., and Saliou P. Vaccines administered simultaneously: directions for new combination vaccines based on an historical review of the literature. Int J Infect Dis 8 (2004) 328-338
11. Russell P.K., Nisalak A., Sukhavachana P., and Vivona S. A plaque reduction test for dengue virus neutralizing antibodies. J Immunol 99 (1967) 291-296
12. Hombach J, Solomon T, Kurane I, Jacobson J, Wood D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September 2004. Vaccine, 2005;23:5205-11.
13. Waraporn T., Pisit S., Sirima P., and Pongtep W. Measles antibody in mothers and infants 0-2 years and response to measles vaccine at the age of 9 and 18 months. J Med Assoc Thai 90 (2007) 106-111
14. Kohler K.A., Suleiman A.J., Robertson S.E., Malankar P., Al-Khusaiby S., Helfand R.F., et al. Immunogenicity of measles and rubella vaccines in Oman: A prospective clinical trial. J Infect Dis 187 (2003) 177-185
15. Semba R.D., Akib A., Beeler J., Munasir Z., Permaesih D., Muherdiyantiningsih, et al. Effect of vitamin A supplementation on measles vaccination in nine-month-old infants. Public Health 111 (1997) 245-247
16. Nkrumah R.K., Osei-Kwasi M., Dunyo S.K., Koram K.A., and Afari E.A. Comparison of AIK-C measles vaccine in infants at 6 months with Schwarz vaccine at 9 months: a randomized controlled trial in Ghana. Bull World Health Organ 76 (1998) 353-359
17. Moriniere B. Serologic responses to two Edmonston-Zagreb measles vaccines in 6-month old infants, and to Schwarz measles vaccine in 9 month old infants (abstract 416). Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Anaheim, CA, 11-14 October 1992 (1992), American Society for Microbiology, Washington, DC
18. Whittle H., Hanlon P., O'Neill K., Hanlon L., Marsh V., Jupp E., et al. Trial of high-dose Edmonston-Zagreb measles vaccine in the Gambia: antibody response and side-effects. Lancet 2 (1988) 811-814
19. Sohn Y.M., Park M.S., Rho H.O., Chandler L.J., Shope R.E., and Tsai T.F. Primary and booster immune responses to SA 14-14-2 Japanese encephalitis vaccine in Korean infants. Vaccine 17 (1999) 2259-2264
20. Ohrr H., Tandan J.B., Sohn Y.M., Shin S.H., Pradhan D.P., and Halstead S.B. Effect of single dose of SA 14-14-2 vaccine 1 year after immunization in Nepalese children with Japanese encephalitis: a case-control study. Lancet 366 (2005) 1375-1378
21. WHO. Report of the Global Advisory Committee on Vaccine Safety, 12-13 December 2007. Wkly Epidemiol Rec 83 4 (2008) 27-44
22. State investigation reports of Adverse Events following Immunization (AEFI) after Japanese Encephalitis (JE) vaccination in high risk districts covering 4 states of the country. Reported in JE flash: http://www.path.org/vaccineresources/files/JEflash_14Nov06.htm.
23. Liu Z.L., Hennessy S., Strom B.L., Tsai T.F., Wan C.M., Tang S.C., et al. Short-term safety of live attenuated Japanese encephalitis vaccine (SA14-14-2): results of a randomized trial with 26 239 subjects. J Infect Dis 176 (1997) 1366-1369
24. Robertson S. The Immunological Basis for Immunization, Module 8: Yellow Fever. WHO/EPI/GEN93 (1993), WHO, Geneva, Switzerland
25. WHO. Inclusion of Yellow Fever vaccine in EPI, Gambia. Wkly Epidemiol Rec 1996; 71:181-85.
26. WHO. Field Guide for District Level Staff on Priority Communicable Disease Surveillance. Brazzaville, Congo: WHO Regional Office for Africa, 1994.
27. Lhuillier M., Mazzariol M.J., Zadi S., Le Cam N., Bentejac M.C., Adamowicz L., et al. Study of combined vaccination against yellow fever and measles in infants from six to nine months. J Biol Stand 17 (1989) 9-15